Hi,
I found a article dated 11/06 on businesswire.com with the headline :
AOP Orphan Announces Progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b
The article mentions that The EUropean Medical Agency will make a final decision on whether Ropeg can be marketed in the EU by Q4 2018.
I will be following this closely as Ropeg seems to be have benefits over HU and other Interferon’s.
John